- Home
- KRKR vs KPRX Comparison
KRKR vs KPRX Comparison
Compare KRKR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRKR
- KPRX
- Stock Information
- Founded
- KRKR 2010
- KPRX 1998
- Country
- KRKR China
- KPRX United States
- Employees
- KRKR N/A
- KPRX N/A
- Industry
- KRKR Business Services
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KRKR Consumer Discretionary
- KPRX Health Care
- Exchange
- KRKR Nasdaq
- KPRX Nasdaq
- Market Cap
- KRKR 10.4M
- KPRX 12.0M
- IPO Year
- KRKR 2019
- KPRX N/A
- Fundamental
- Price
- KRKR $4.15
- KPRX $3.47
- Analyst Decision
- KRKR
- KPRX Strong Buy
- Analyst Count
- KRKR 0
- KPRX 1
- Target Price
- KRKR N/A
- KPRX $10.00
- AVG Volume (30 Days)
- KRKR 1.3M
- KPRX 46.3K
- Earning Date
- KRKR 04-17-2025
- KPRX 03-24-2025
- Dividend Yield
- KRKR N/A
- KPRX N/A
- EPS Growth
- KRKR N/A
- KPRX N/A
- EPS
- KRKR N/A
- KPRX 1.69
- Revenue
- KRKR $41,654,350.00
- KPRX $16,020,000.00
- Revenue This Year
- KRKR $45.99
- KPRX N/A
- Revenue Next Year
- KRKR $31.46
- KPRX N/A
- P/E Ratio
- KRKR N/A
- KPRX $2.05
- Revenue Growth
- KRKR N/A
- KPRX N/A
- 52 Week Low
- KRKR $2.76
- KPRX $3.00
- 52 Week High
- KRKR $12.99
- KPRX $6.75
- Technical
- Relative Strength Index (RSI)
- KRKR 46.65
- KPRX 44.69
- Support Level
- KRKR $3.30
- KPRX $3.40
- Resistance Level
- KRKR $6.20
- KPRX $3.75
- Average True Range (ATR)
- KRKR 1.03
- KPRX 0.22
- MACD
- KRKR -0.24
- KPRX -0.03
- Stochastic Oscillator
- KRKR 22.84
- KPRX 37.65
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.